Menaouar Ahmed, Florian Maria, Wang Donghao, Danalache Bogdan, Jankowski Marek, Gutkowska Jolanta
Cardiovascular Biochemistry Laboratory, CRCHUM, Department of Medicine, University of Montreal Quebec, Canada.
Int J Cardiol. 2014 Jul 15;175(1):38-49. doi: 10.1016/j.ijcard.2014.04.174. Epub 2014 Apr 26.
Oxytocin (OT) and functional OT receptor (OTR) are expressed in the heart and are involved in blood pressure regulation and cardioprotection. Cardiac OTR signaling is associated with atrial natriuretic peptide (ANP) and nitric oxide (NO) release. During the synthesis of OT, its precursor, termed OT-Gly-Lys-Arg (OT-GKR), is accumulated in the developing rat heart. Consequently, we hypothesized that an OT-related mechanism of ANP controls cardiomyocyte (CM) hypertrophy.
The experiments were carried out in newborn and adult rat CM cultures. The enhanced protein synthesis and increased CM volume were mediated by a 24-h treatment with endothelin-1 or angiotensin II.
The treatment of CM with OT or its abundant cardiac precursor, OT-GKR, revealed ANP accumulation in the cell peri-nuclear region and increased intracellular cGMP. Consequently, the CM hypertrophy was abolished by the treatment of 10nM OT or 10nM OT-GKR. The ANP receptor antagonist (anantin) and NO synthases inhibitor (l-NAME) inhibited cGMP production in CMs exposed to OT. STO-609 and compound C inhibition of anti-hypertrophic OT effects in CMs indicated the contribution of calcium-calmodulin kinase kinase and AMP-activated protein kinase pathways. Moreover, in ET-1 stimulated cells, OT treatment normalized the reduced Akt phosphorylation, prevented abundant accumulation of ANP and blocked ET-1-mediated translocation of nuclear factor of activated T-cells (NFAT) into the cell nuclei.
cGMP/protein kinase G mediates OT-induced anti-hypertrophic response with the contribution of ANP and NO. OT treatment represents a novel approach in attenuation of cardiac hypertrophy during development and cardiac pathology.
催产素(OT)和功能性催产素受体(OTR)在心脏中表达,并参与血压调节和心脏保护。心脏OTR信号传导与心房利钠肽(ANP)和一氧化氮(NO)释放有关。在OT合成过程中,其前体OT-甘氨酸-赖氨酸-精氨酸(OT-GKR)在发育中的大鼠心脏中积累。因此,我们推测ANP的OT相关机制控制心肌细胞(CM)肥大。
实验在新生和成年大鼠CM培养物中进行。内皮素-1或血管紧张素II处理24小时介导蛋白质合成增强和CM体积增加。
用OT或其丰富的心脏前体OT-GKR处理CM,显示ANP在细胞核周区域积累并增加细胞内cGMP。因此,10nM OT或10nM OT-GKR处理可消除CM肥大。ANP受体拮抗剂(安那替明)和NO合酶抑制剂(L-NAME)抑制暴露于OT的CM中的cGMP产生。STO-609和化合物C对CM中抗肥大OT作用的抑制表明钙调蛋白激酶激酶和AMP活化蛋白激酶途径的作用。此外,在ET-1刺激的细胞中,OT处理使降低的Akt磷酸化正常化,防止ANP大量积累,并阻断ET-1介导的活化T细胞核因子(NFAT)向细胞核的转位。
cGMP/蛋白激酶G介导OT诱导的抗肥大反应,其中ANP和NO起作用。OT治疗是在发育过程中和心脏病理状态下减轻心脏肥大的一种新方法。